Open an account

NRX Pharmaceuticals

NRXP · NASDAQ

$2.62−$0.01 (−0.38%)TodayMarket closed ·
Prev close $2.63

About NRXP

NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is headquartered in Wilmington, Delaware and currently employs 29 full-time employees. The company went IPO on 2017-11-20. The company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.

Employees
29
Headquarters
Wilmington, Delaware
Listed
Nov 20, 2017
Sector
Health Care
Industry
Pharmaceuticals
Website
nrxpharma.com

NRXP key statistics

Market cap
113.43M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
673.29K
Volume
1.35M
Open price
$2.63
High today
$2.77
Low today
$2.55
52 Week high
$5.06
52 Week low
$1.62

NRX Pharmaceuticals (NRXP) at a glance

As of Oct 20, 2026, NRX Pharmaceuticals (NRXP) shares are priced at $2.62, giving the company a market cap of 113.43M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.55 and $2.77. The current price is 2.9% above the day's low and 5.4% below its high.

Volume so far is 1.35M shares, above the average of 673.29K shares a day.

Over the past year NRX Pharmaceuticals has ranged from $1.62 to $5.06, and now sits 29% of the way up that range.

NRX Pharmaceuticals met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported -$0.44 per share against an estimate of $0.0653.

The average analyst price target is $39.27, 1398.9% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 4 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $39.27
Low
$10.10
Now
$2.62
High
$52.50

NRXP earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 55.7% on average.

  1. Q3 FY24: reported -$0.13 per share against an estimate of -$0.6528
  2. Q4 FY24: reported -$0.77 per share against an estimate of -$0.323
  3. Q1 FY25: reported -$0.21 per share against an estimate of -$0.306
  4. Q2 FY25: reported -$0.31 per share against an estimate of -$0.2074
  5. Q3 FY25: reported -$0.50 per share against an estimate of -$0.0867
  6. Q4 FY25: reported -$0.012 per share against an estimate of -$0.0026
  7. Q1 FY26: reported -$0.04 per share against an estimate of $0.2932
  8. Q2 FY26: reported -$0.44 per share against an estimate of $0.0653

NRXP news

  • Press releaseBusiness Wire

    Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition

  • Press releasePRNewswire

    ZETA SURGICAL® Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE Therapeutics

  • Press releaseGlobe Newswire

    NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression

  • Tanya Rawat

    NRx Pharmaceuticals (NRXP) Stock Fell 19% After Hours On Tuesday: Here's Why

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • 12 Health Care Stocks Moving In Friday's After-Market Session

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • Press releasePRNewswire

    NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results Release to August 19, 2025

Similar companies

Companies in the same industry as NRX Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.